Long-term survival of patients (pts) with advanced melanoma treated with ipilimumab with or without dacarbazine

被引：0
|
作者：
Hersh, E.
Weber, J.
Powderly, J.
Pavlik, A.
Nichol, G.
Yellin, M.
Cranmer, L.
Urba, W.
O'Day, S.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Comprehens Melanoma Res Ctr, Tampa, FL USA
[3] Carolina BioOncol Inst, Hunterville, NC USA
[4] NYU, Med Ctr, New York, NY 10016 USA
[5] Medarex Inc, Bloomsbury, NJ USA
[6] Providence Portland Med Ctr, Portland, OR USA
[7] Angeles Clin, Res Inst, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9038
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ipilimumab In Previously Treated Patients with Advanced Melanoma
    Sanford, Mark
    BIODRUGS, 2012, 26 (03) : 185 - 193
  • [22] Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma
    Long, Georgina V.
    Larkin, James
    Schadendorf, Dirk
    Grob, Jean-Jacques
    Lao, Christopher D.
    Marquez-Rodas, Ivan
    Wagstaff, John
    Lebbe, Celeste
    Pigozzo, Jacopo
    Robert, Caroline
    Ascierto, Paolo A.
    Atkinson, Victoria
    Postow, Michael A.
    Atkins, Michael B.
    Sznol, Mario
    Callahan, Margaret K.
    Topalian, Suzanne L.
    Sosman, Jeffrey A.
    Kotapati, Srividya
    Thakkar, Pratik K.
    Ritchings, Corey
    Benito, Melanie Pe
    Re, Sandra
    Soleymani, Samira
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (08)
  • [23] Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma
    Krajsova, Ivana
    Arenberger, Petr
    Lakomy, Radek
    Kubala, Eugen
    Brezinova, Ivana
    Poprach, Alexandr
    Stastny, Marek
    Muzik, Jan
    Melichar, Bohuslav
    ANTICANCER RESEARCH, 2015, 35 (11) : 6303 - 6310
  • [24] Long-term survival benefit from ipilimumab treatment in metastatic uveal melanoma patients.
    Deo, Mugdha Anand
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Evaluation of the Long-Term Survival after Treatment with Ipilimumab or Vemurafenib in Patients with Metastatic Malignant Melanoma
    Rudolph, B. M.
    Groffik, A.
    Faidt, D.
    Grabbe, S.
    Loquai, C.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2014, 12 : 2 - 3
  • [26] A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
    Evan M. Hersh
    Steven J. O’Day
    John Powderly
    Khuda D. Khan
    Anna C. Pavlick
    Lee D. Cranmer
    Wolfram E. Samlowski
    Geoffrey M. Nichol
    Michael J. Yellin
    Jeffrey S. Weber
    Investigational New Drugs, 2011, 29 : 489 - 498
  • [27] Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
    Rogiers, Anne
    Boekhout, Annelies
    Schwarze, Julia K.
    Awada, Gil
    Blank, Christian U.
    Neyns, Bart
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [28] Emotional and cognitive disturbances in long-term melanoma survivors treated with ipilimumab.
    Rogiers, Anne
    Awada, Gil
    Schwarze, Julia
    De Cremer, Jennifer
    Ben Salama, Laila
    Theuns, Peter
    Neyns, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [29] Long-term results with nivolumab and ipilimumab in melanoma
    Giacco, Vincenzo
    NATURE CANCER, 2025, 6 (03) : 407 - 407
  • [30] Gauging the Long-Term Benefits of Ipilimumab in Melanoma
    Ribas, Antoni
    Flaherty, Keith T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1865 - U11
12345